Tumorschmerz

142 / 156

140
Nr. Nachweis
204 Meissner W, Leyendecker P, Mueller-Lissner S, Nadstawek J, Hopp M, Ruckes C, Wirz
S,Fleischer W, Reimer K. A randomised controlled trial with prolonged-release oral oxyco-
done and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 2009;
13(1): 56-64.
205 Mercadante S, Bruera E. Opioid switching: a systematic and critical review. Cancer Treat
Rev 2006; 32(4): 304-315.
206 Mercadante S, Ferrera P, Arcuri E. The use of fentanyl buccal tablets as breakthrough
medication in patients receiving chronic methadone therapy: an open label preliminary
study. Support Care Cancer 2011; 19(3): 435-438.
207 Mercadante S, Intravaia G, Villari P, Ferrera P, David F, Casuccio A. Controlled sedation for
refractory symptoms in dying patients. J Pain Symptom Manage 2009; 37(5): 771-779.
208 Mercadante S, Intravaia G, Villari P, Ferrera P, Riina S, David F, Mangione S. Intrathecal
treatment in cancer patients unresponsive to multiple trials of systemic opioids. Clin J
Pain 2007; 23(9): 793-798.
209 Mercadante S, Intravaia G, Villari P, Ferrera P, Riina S, Mangione S. Intravenous morphine
for breakthrough (episodic-) pain in an acute palliative care unit: a confirmatory study. J
Pain Symptom Manage 2008; 35(3): 307-313.
210 Mercadante S, Porzio G, Ferrera P, Aielli F, Adile C, Ficorella C. Low doses of transdermal
fentanyl in opioid-naive patients with cancer pain. Curr Med Res Opin 2010; 26(12):
2765-2768.
211 Mercadante S, Porzio G, Ferrera P, Aielli F, Verna L, Tirelli W, Villari P, Casuccio A. Low
doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week,
nonrandomized, open-label, uncontrolled observational study. Clin Ther 2009; 31(10):
2134-2138.
212 Mercadante S, Porzio G, Ferrera P, Fulfaro F, Aielli F, Ficorella C, Verna L, Tirelli W, Villari P,
Arcuri E. Low morphine doses in opioid-naive cancer patients with pain. J Pain Symptom
Manage 2006; 31(3): 242-247.
213 Mercadante S, Porzio G, Ferrera P, Fulfaro F, Aielli F, Verna L, Villari P, Ficorella C, Gebbia
V, Riina S, Casuccio A, Mangione S. Sustained-release oral morphine versus transdermal
fentanyl and oral methadone in cancer pain management. Eur J Pain 2008; 12(8): 1040-
1046.
214 Mercadante S, Radbruch L, Davies A, Poulain P, Sitte T, Perkins P, Colberg T, Camba MA.
A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the
treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. Curr
Med Res Opin 2009; 25(11): 2805-2815.
215 Mercadante S, Tirelli W, David F, Arcara C, Fulfaro F, Casuccio A, Gebbia V. Morphine
versus oxycodone in pancreatic cancer pain: a randomized controlled study. Clin J Pain
2010; 26(9): 794-797.
216 Mercadante S, Villari P, Ferrera P, Casuccio A, Mangione S, Intravaia G. Transmucosal
fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for
episodic-breakthrough pain. Br J Cancer 2007; 96(12): 1828-1833.
Literaturverzeichnis